As of 2024-12-15, the Relative Valuation of BioCryst Pharmaceuticals Inc (BCRX) is (16.36) USD. This relative valuation is based on P/E multiples. With the latest stock price at 7.53 USD, the upside of BioCryst Pharmaceuticals Inc based on Relative Valuation is -317.3%.
The range of the Relative Valuation is (11.60) - (20.56) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 17.3x - 34.4x | 25.8x |
| Forward P/E multiples | 19.4x - 38.4x | 28.9x |
| Fair Price | (11.60) - (20.56) | (16.36) |
| Upside | -254.0% - -373.1% | -317.3% |
| Date | P/E |
| 2024-12-13 | -12.60 |
| 2024-12-12 | -12.71 |
| 2024-12-11 | -13.15 |
| 2024-12-10 | -13.27 |
| 2024-12-09 | -12.93 |
| 2024-12-06 | -12.73 |
| 2024-12-05 | -13.12 |
| 2024-12-04 | -12.26 |
| 2024-12-03 | -12.03 |
| 2024-12-02 | -12.35 |
| 2024-11-29 | -12.55 |
| 2024-11-27 | -12.55 |
| 2024-11-26 | -12.53 |
| 2024-11-25 | -12.16 |
| 2024-11-22 | -12.71 |
| 2024-11-21 | -12.53 |
| 2024-11-20 | -12.21 |
| 2024-11-19 | -12.06 |
| 2024-11-18 | -11.81 |
| 2024-11-15 | -11.76 |
| 2024-11-14 | -12.46 |
| 2024-11-13 | -12.78 |
| 2024-11-12 | -13.08 |
| 2024-11-11 | -13.70 |
| 2024-11-08 | -13.01 |
| 2024-11-07 | -12.83 |
| 2024-11-06 | -12.93 |
| 2024-11-05 | -11.80 |
| 2024-11-04 | -12.30 |
| 2024-11-01 | -14.10 |
| 2024-10-31 | -13.40 |
| 2024-10-30 | -14.00 |
| 2024-10-29 | -13.58 |
| 2024-10-28 | -13.63 |
| 2024-10-25 | -13.30 |
| 2024-10-24 | -13.68 |
| 2024-10-23 | -13.48 |
| 2024-10-22 | -13.30 |
| 2024-10-21 | -12.58 |
| 2024-10-18 | -12.75 |
| 2024-10-17 | -12.53 |
| 2024-10-16 | -12.66 |
| 2024-10-15 | -12.51 |
| 2024-10-14 | -12.48 |
| 2024-10-11 | -12.43 |
| 2024-10-10 | -11.91 |
| 2024-10-09 | -12.13 |
| 2024-10-08 | -12.04 |
| 2024-10-07 | -12.45 |
| 2024-10-04 | -12.68 |